FATE THERAPEUTICS INC (FATE)

US31189P1021 - Common Stock

1.68  +0.02 (+1.2%)

After market: 1.6802 +0 (+0.01%)

FATE THERAPEUTICS INC

NASDAQ:FATE (12/20/2024, 8:08:19 PM)

After market: 1.6802 +0 (+0.01%)

1.68

+0.02 (+1.2%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%13.04%
Sales Q2Q%58.13%
CRS4.01
6 Month-55.32%
Overview
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Ins Owners2.14%
Inst Owners107.11%
Market Cap191.34M
Shares113.89M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts73.33
Short Float %10.37%
Short Ratio3.97
IPO10-01 2013-10-01
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

FATE Daily chart

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. The firm is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

Company Info

FATE THERAPEUTICS INC

12278 Scripps Summit Drive

San Diego CALIFORNIA 92121

P: 18588751803

CEO: J. Scott Wolchko

Employees: 181

Website: https://fatetherapeutics.com/

FATE News

News Image13 days ago - Fate Therapeutics, Inc.Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
News Image13 days ago - Fate Therapeutics, Inc.Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with...

News Image19 days ago - Fate Therapeutics, Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
News Image19 days ago - Fate Therapeutics, Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...

News Image24 days ago - Fate Therapeutics, Inc.Fate Therapeutics Announces Leadership Transition
News Image24 days ago - Fate Therapeutics, Inc.Fate Therapeutics Announces Leadership Transition

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in...

FATE Twits

Here you can normally see the latest stock twits on FATE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example